Journal article
A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer
HM Lin, KL Mahon, JM Weir, PA Mundra, C Spielman, K Briscoe, H Gurney, G Mallesara, G Marx, MR Stockler, C Prime, RG Parton, AJ Hoy, RJ Daly, PJ Meikle, LG Horvath
International Journal of Cancer | WILEY | Published : 2017
DOI: 10.1002/ijc.30903
Abstract
Lipids are known to influence tumour growth, inflammation and chemoresistance. However, the association of circulating lipids with the clinical outcome of metastatic castration-resistant prostate cancer (CRPC) is unknown. We investigated associations between the plasma lipidome and clinical outcome in CRPC. Lipidomic profiling by liquid chromatography-tandem mass spectrometry was performed on plasma samples from a Phase 1 discovery cohort of 96 CRPC patients. Results were validated in an independent Phase 2 cohort of 63 CRPC patients. Unsupervised analysis of lipidomic profiles (323 lipid species) classified the Phase 1 cohort into two patient subgroups with significant survival differences ..
View full abstractGrants
Awarded by Prostate Cancer Foundation of Australia
Funding Acknowledgements
Grant sponsor: National Health and Medical Research Council of Australia; Grant numbers: 1042095 (to P.J.M.), 1058540 (to R.J.D.) and 535903; Grant sponsor: Operational Infrastructure Support Program of the Victorian Government; Grant sponsor: Cancer Institute New South Wales; Grant number: 10/TPG/1-04; Grant sponsor: Cancer Council New South Wales; Grant number: PG 10-01; Grant sponsor: Prostate Cancer Foundation of Australia (Movember Clinician Scientist Award to K.L.M., Movember Revolutionary Team Award to A.J.H.)